Activity from announced rounds
RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.
Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease
Develops high-efficiency quantum memories for next-generation quantum computing systems
Builds an AI reasoning engine to generate scientific hypotheses across chemistry, materials science, and biology for industrial R&D
Developer of standardized upgrades that increase output from existing nuclear power plants.